|This article needs additional citations for verification. (April 2009) (Learn how and when to remove this template message)|
|Public company (LSE: OXB)|
|Revenue||1.5 Million US$ (Dec 2008)|
Number of employees
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. It was established in 1995 as a spin out from Oxford University. The lead product is TroVax, a therapeutic cancer vaccine for multiple solid cancers, which is in Phase III development in collaboration with Sanofi-Aventis. TroVax failed in a key kidney cancer test in 2008 which caused a dramatic drop in Oxford BioMedica's share price The Company’s advanced development pipeline includes treatments for cancer, Parkinson's disease and retinopathy. The company's early stage development pipeline includes preclinical candidates for Stargardt disease, motor neuron disease, spinal muscular atrophy and AIDS.
|This section needs additional citations for verification. (April 2009) (Learn how and when to remove this template message)|
To date, the Company has raised a total of £137 million to fund its research and clinical programmes. The IPO on the Alternative Investment Market of the London Stock Exchange in December 1996 raised £5.1 million.
A further £6 million was raised by a rights issue and placing in March/April 1998, £3.6 million by a rights issue in March 1999, £5.2 million in a Placing in January 2000 and £8.8 million in a Placing in August 2000.
Oxford BioMedica's move to the official list of the London Stock Exchange was completed in April 2001 along with a £35.5 million fund raising, before costs, from a placing and open offer.
A Rights Issue for £22.1 million, before costs, was completed in October 2003. A further share offering in December 2005 raised £30.1 million before expenses, including an investment of £2.9 million by Sigma-Aldrich [better source needed]. A placing and open offer in December 2010 raised £20 million.